Clinical Trial

Clinical Study of CVL006 Injection in Advanced Solid Tumors

Name: Clinical Study of CVL006 Injection in Advanced Solid Tumors — clinical trial record (NCT06621615)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Evaluate the safety and tolerability of CVL006 monotherapy in patients with advanced solid tumors; Observe the dose limiting toxicity (DLT) of CVL006 monotherapy in patients with advanced solid tumors, evaluate the maximum tolerated dose (MTD), and recommend the dosage for phase II clinical trials (RP2D).

Trial Details

NCT Number	NCT06621615
Lead Sponsor	Convalife (Shanghai) Co., Ltd.
Conditions	Advanced Solid Tumor
Enrollment	120 participants
Start Date	2024-11-20
Primary Completion	2028-05-20 (estimated)
Study Completion	2028-11-20 (estimated)
Updated on ClinicalTrials.gov	2024-10-01